Decibel Therapeutics (NASDAQ:DBTX – Get Rating)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report released on Wednesday, Benzinga reports. They currently have a $23.00 price objective on the stock. HC Wainwright also issued estimates for Decibel Therapeutics’ FY2027 earnings at ($0.52) EPS.
Several other research analysts have also issued reports on the company. SVB Securities lowered Decibel Therapeutics from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $7.00 to $2.00 in a research report on Wednesday. SVB Leerink lowered their target price on Decibel Therapeutics from $10.00 to $7.00 and set an “outperform” rating for the company in a research report on Monday, January 23rd. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.80.
Decibel Therapeutics Stock Performance
Shares of DBTX opened at $3.73 on Wednesday. Decibel Therapeutics has a 52 week low of $1.61 and a 52 week high of $5.78. The stock has a market capitalization of $93.14 million, a price-to-earnings ratio of -1.57 and a beta of -0.02. The stock has a fifty day moving average of $3.65 and a 200-day moving average of $3.48.
Institutional Trading of Decibel Therapeutics
Decibel Therapeutics Company Profile
Decibel Therapeutics, Inc, a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin.
- Get a free copy of the StockNews.com research report on Decibel Therapeutics (DBTX)
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
- A Weakening Economy Suggests Caution Before Buying Five Below
- Williams-Sonoma: Time To Buy At Rock-Bottom Prices
- Why DraftKings Could Keep Outperforming in 2023
- Charles Schwab And The Safest 30% You Can Make This Year
Receive News & Ratings for Decibel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Decibel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.